Lipid phosphatases as drug discovery targets for type 2 diabetes

Nature Reviews Drug Discovery

Volumn 5, Issue 4, 2006, Pages 333-342

  Lazar, Dan F ^a   Saltiel, Alan R ^b  

^a ELI LILLY AND COMPANY   (United States)

^b Life Sciences Institute   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADIPONECTIN; ENZYME INHIBITOR; INSULIN; INSULIN RECEPTOR; MITOGEN ACTIVATED PROTEIN KINASE; PHOSPHATIDYLINOSITOL 3 KINASE; PHOSPHATIDYLINOSITOL 3,4,5 TRISPHOSPHATE 3 PHOSPHATASE; PROTEIN KINASE B; PROTEIN TYROSINE PHOSPHATASE SHP 1; PROTEIN TYROSINE PHOSPHATASE SHP 2;

DRUG RESEARCH; DRUG TARGETING; ENERGY METABOLISM; ENZYME ACTIVATION; ENZYME ACTIVITY; GENE OVEREXPRESSION; INSULIN BINDING; INSULIN RESISTANCE; NON INSULIN DEPENDENT DIABETES MELLITUS; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN PHOSPHORYLATION; PROTEIN STRUCTURE; REGULATORY MECHANISM; REVIEW; SIGNAL TRANSDUCTION; WEIGHT GAIN;

1-PHOSPHATIDYLINOSITOL 3-KINASE; ANIMALS; DIABETES MELLITUS, TYPE 2; DRUG DESIGN; ENERGY METABOLISM; ENZYME INHIBITORS; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN; PHOSPHORIC MONOESTER HYDROLASES; PTEN PHOSPHOHYDROLASE; RECEPTOR, INSULIN; SIGNAL TRANSDUCTION;

EID: 33645466144     PISSN: 14741776     EISSN: 14741784     Source Type: Journal    
DOI: 10.1038/nrd2007     Document Type: Review

References (129)

1. Amos, A. F., McCarty, D. J. & Zimmet, P. The rising global burden of diabetes and its complications: Estimates and projections to the year 2010. Diabet. Med. 14 (Suppl. 5), S1-S85 (1997).
2. Pessin, J. E. & Saltiel, A. R. Signaling pathways in insulin action: molecular targets of insulin resistance. J. Clin. Invest. 106, 165-169 (2000).
3. Shulman, G. I. Cellular mechanisms of insulin resistance. J. Clin. Invest. 106, 171-176 (2000).
4. Saltiel, A. R. & Kahn, C. R. Insulin signalling and the regulation of glucose and lipid metabolism. Nature 414, 799-806 (2001).
5. Patti, M. E. & Kahn, C. R. The insulin receptor-a critical link in glucose homeostasis and insulin action. J. Basic Clin. Physiol. Pharmacol. 9, 89-109 (1998).
6. White, M. F. The IRS-signalling system: A network of docking proteins that mediate insulin action. Mol. Cell. Biochem. 182, 3-11 (1998).
7. Sun, X. J. et al. Role of IRS-2 in insulin and cytokine signalling. Nature 377, 173-177 (1995).
8. Lavan, B. E. et al. A novel 160-kDa phosphotyrosine protein in insulin-treated embryonic kidney cells is a new member of the insulin receptor substrate family. J. Biol. Chem. 272, 21403-21407 (1997).
9. Lavan, B. E., Lane, W. S. & Lienhard, G. E. The 60-kDa phosphotyrosine protein in insulin-treated adipocytes is a new member of the insulin receptor substrate family. J. Biol. Chem. 272, 11439-11443 (1997).
10. Sasaoka, T. et al. Evidence for a functional role of Shc proteins in mitogenic signaling induced by insulin, insulin-like growth factor-1, and epidermal growth factor. J. Biol. Chem. 269, 13689-13694 (1994).
11. Liu, J., Kimura, A., Baumann, C. A. & Saltiel, A. R. APS facilitates c-Cbl tyrosine phosphorylation and GLUT4 translocation in response to insulin in 3T3-L1 adipocytes. Mol. Cell. Biol. 22, 3599-3609 (2002).
12. Ribon, V. & Saltiel, A. R. Insulin stimulates tyrosine phosphorylation of the proto-oncogene product of c-Cbl in 3T3-L1 adipocytes. Biochem. J. 324, 839-845 (1997).
13. Holgado-Madruga, M., Emlet, D. R., Moscatello, D. K., Godwin, A. K. & Wong, A. J. A Grb2-associated docking protein in EGF- and insulin-receptor signalling. Nature 379, 560-564 (1996).
14. Withers, D. J. et al. Disruption of IRS-2 causes type 2 diabetes in mice. Nature 391, 900-904 (1998).
15. Tamemoto, H. et al. Insulin resistance and growth retardation in mice lacking insulin receptor substrate-1. Nature 372, 182-186 (1994).
16. Araki, E. et al. Alternative pathway of insulin signalling in mice with targeted disruption of the IRS-1 gene. Nature 372, 186-190 (1994).
17. Bruning, J. C. et al. Development of a novel polygenic model of NIDDM in mice heterozygous for IR and IRS-1 null alleles. Cell 88, 561-572 (1997).
18. Kido, Y., Nakae, J. & Accili, D. Clinical review 125: The insulin receptor and its cellular targets. J. Clin. Endocrinol. Metab. 86, 972-979 (2001).
19. Okada, T., Kawano, Y., Sakakibara, T., Hazeki, O. & Ui, M. Essential role of phosphatidylinositol 3-kinase in insulin-induced glucose transport and antilipolysis in rat adipocytes. Studies with a selective inhibitor wortmannin. J. Biol. Chem. 269, 3568-3573 (1994).
20. Cheatham, B. et al. Phosphatidylinositol 3-kinase activation is required for insulin stimulation of pp70 S6 kinase, DNA synthesis, and glucose transporter translocation. Mol. Cell. Biol. 14, 4902-4911 (1994).
21. Evans, J. L., Honer, C. M., Womelsdorf, B. E., Kaplan, E. L. & Bell, P. A. The effects of wortmannin, a potent inhibitor of phosphatidylinositol 3-kinase, on insulin-stimulated glucose transport, GLUT4 translocation, antilipolysis, and DNA synthesis. Cell Signal. 7, 365-376 (1995).
22. Quon, M. J. et al. Roles of 1-phosphatidylinositol 3-kinase and ras in regulating translocation of GLUT4 in transfected rat adipose cells. Mol. Cell. Biol. 15, 5403-5411 (1995).
23. Martin, S. S. et al. Activated phosphatidylinositol 3-kinase is sufficient to mediate actin rearrangement and GLUT4 translocation in 3T3-L1 adipocytes. J. Biol. Chem. 271, 17605-17608 (1996).
24. Vanhaesebroeck, B. & Alessi, D. R. The PI3K-PDK1 connection: More than just a road to PKB. Biochem. J. 346, 561-576 (2000).
25. Mora, A., Komander, D., van Aalten, D. M. & Alessi, D. R. PDK1, the master regulator of AGC kinase signal transduction. Semin. Cell Dev. Biol. 15, 161-170 (2004).
26. Sarbassov, D. D., Guertin, D. A., Ali, S. M. & Sabatini, D. M. Phosphorylation and regulation of Akt/PKB by the rictor-mTOR complex. Science 307, 1098-1101 (2005).
27. Niswender, K. D. et al. Insulin activation of phosphatidylinositol 3-kinase in the hypothalamic arcuate nucleus: A key mediator of insulin-induced anorexia. Diabetes 52, 227-231 (2003).
28. Carvalheira, J. B. et al. Selective impairment of insulin signalling in the hypothalamus of obese Zucker rats. Diabetologia 46, 1629-1640 (2003).
29. Niswender, K. D. et al. Intracellular signalling. Key enzyme in leptin-induced anorexia. Nature 413, 794-795 (2001).
30. Zhao, A. Z., Huan, J. N., Gupta, S., Pal, R. & Sahu, A. A phosphatidylinositol 3-kinase phosphodiesterase 3B-cyclic AMP pathway in hypothalamic action of leptin on feeding. Nature Neurosci. 5, 727-728 (2002).
31. Rahmouni, K., Haynes, W. G., Morgan, D. A. & Mark, A. L. Intracellular mechanisms involved in leptin regulation of sympathetic outflow. Hypertension 41, 763-767 (2003).
32. Goberdhan, D. C. & Wilson, C. PTEN: Tumour suppressor, multifunctional growth regulator and more. Hum. Mol. Genet. 12, R239-R248 (2003).
33. Leslie, N. R. & Downes, C. P. PTEN function: How normal cells control it and tumour cells lose it. Biochem. J. 382, 1-11 (2004).
34. Ogg, S. & Ruvkun, G. The C. elegans PTEN homolog, DAF-18, acts in the insulin receptor-like metabolic signaling pathway. Mol. Cell 2, 887-893 (1998).
35. Goberdhan, D. C., Paricio, N., Goodman, E. C., Mlodzik, M. & Wilson, C. Drosophila tumor suppressor PTEN controls cell size and number by antagonizing the Chico/PI3-kinase signaling pathway. Genes Dev. 13, 3244-3258 (1999).
36. Nakashima, N., Sharma, P. M., Imamura, T., Bookstein, R. & Olefsky, J. M. The tumor suppressor PTEN negatively regulates insulin signaling in 3T3-L1 adipocytes. J. Biol. Chem. 275, 12889-12895 (2000).
37. Ono, H. et al. Regulation of phosphoinositide metabolism, Akt phosphorylation, and glucose transport by PTEN (phosphatase and tensin homolog deleted on chromosome 10) in 3T3-L1 adipocytes. Mol. Endocrinol. 15, 1411-1422 (2001).
38. Mosser, V. A., Li, Y. & Quon, M. J. PTEN does not modulate GLUT4 translocation in rat adipose cells under physiological conditions. Biochem. Biophys. Res. Commun. 288, 1011-1017 (2001).
39. Tang, X., Powelka, A. M., Soriano, N. A., Czech, M. P. & Guilherme, A. PTEN, but not SHIP2, suppresses insulin signaling through the phosphatidylinositol 3-kinase/Akt pathway in 3T3-L1 adipocytes. J. Biol. Chem. 280, 22523-22529 (2005).
40. Seo, J. H., Ahn, Y., Lee, S. R., Yeol Yeo, C. & Chung Hur, K. The major target of the endogenously generated reactive oxygen species in response to insulin stimulation is phosphatase and tensin homolog and not phosphoinositide-3 kinase (PI-3 kinase) in the PI-3 kinase/Akt pathway. Mol. Biol. Cell 16, 348-357 (2005).
41. Butler, M. et al. Specific inhibition of PTEN expression reverses hyperglycemia in diabetic mice. Diabetes 51, 1028-1034 (2002).
42. Horie, Y. et al. Hepatocyte-specific Pten deficiency results in steatohepatitis and hepatocellular carcinomas. J. Clin. Invest. 113, 1774-1783 (2004).
43. Stiles, B. et al. Liver-specific deletion of negative regulator Pten results in fatty liver and insulin hypersensitivity [corrected]. Proc. Natl Acad. Sci. USA 101, 2082-2087 (2004).
44. Wijesekara, N. et al. Muscle-specific Pten deletion protects against insulin resistance and diabetes. Mol. Cell. Biol. 25, 1135-1145 (2005).
45. Kurlawalla-Martinez, C. et al. Insulin hypersensitivity and resistance to streptozotocin-induced diabetes in mice lacking PTEN in adipose tissue. Mol. Cell. Biol. 25, 2498-2510 (2005).
46. Lo, Y. T., Tsao, C. J., Liu, I. M., Liou, S. S. & Cheng, J. T. Increase of PTEN gene expression in insulin resistance. Horm. Metab. Res. 36, 662-666 (2004).
47. Hansen, L. et al. Studies of variability in the PTEN gene among Danish caucasian patients with Type II diabetes mellitus. Diabetologia 44, 237-240 (2001).
48. Ishihara, H. et al. Association of the polymorphisms in the 5′-untranslated region of PTEN gene with type 2 diabetes in a Japanese population. FEBS Lett. 554, 450-454 (2003).
49. Rohrschneider, L. R., Fuller, J. F., Wolf, I., Liu, Y. & Lucas, D. M. Structure, function, and biology of SHIP proteins. Genes Dev. 14, 505-520 (2000).
50. Pesesse, X., Deleu, S., De Smedt, F., Drayer, L. & Erneux, C. Identification of a second SH2-domaincontaining protein closely related to the phosphatidylinositol polyphosphate 5-phosphatase SHIP. Biochem. Biophys. Res. Commun. 239, 697-700 (1997).
51. Backers, K., Blero, D., Paternotte, N., Zhang, J. & Erneux, C. The termination of PI3K signalling by SHIP1 and SHIP2 inositol 5-phosphatases. Adv. Enzyme Regul. 43, 15-28 (2003).
52. Chi, Y. et al. Comparative mechanistic and substrate specificity study of inositol polyphosphate 5-phosphatase Schizosaccharomyces pombe Synaptojanin and SHIP2. J. Biol. Chem. 279, 44987-44995 (2004).
53. Kalesnikoff, J. et al. The role of SHIP in cytokineinduced signaling. Rev. Physiol. Biochem. Pharmacol. 149, 87-103 (2003).
54. Sleeman, M. W. et al. Absence of the lipid phosphatase SHIP2 confers resistance to dietary obesity. Nature Med. 11, 199-205 (2005).
55. Ishihara, H. et al. Membrane localization of Src homology 2-containing inositol 5′-phosphatase 2 via Shc association is required for the negative regulation of insulin signaling in Rat1 fibroblasts overexpressing insulin receptors. Mol. Endocrinol. 16, 2371-2381 (2002).
56. Dyson, J. M. et al. The SH2-containing inositol polyphosphate 5-phosphatase, SHIP-2, binds filamin and regulates submembraneous actin. J. Cell. Biol. 155, 1065-1079 (2001).
57. Damen, J. E., Ware, M. D., Kalesnikoff, J., Hughes, M. R. & Krystal, G. SHIP's C-terminus is essential for its hydrolysis of PIP3 and inhibition of mast cell degranulation. Blood 97, 1343-1351 (2001).
58. Liu, L. et al. The Src homology 2 (SH2) domain of SH2-containing inositol phosphatase (SHIP) is essential for tyrosine phosphorylation of SHIP, its association with Shc, and its induction of apoptosis. J. Biol. Chem. 272, 8983-8988 (1997).
59. Dyson, J. M. et al. The SH2 domain containing inositol polyphosphate 5-phosphatase-2: SHIP2. Int. J. Biochem. Cell Biol. 37, 2260-2265 (2005).
60. Habib, T., Hejna, J. A., Moses, R. E. & Decker, S. J. Growth factors and insulin stimulate tyrosine phosphorylation of the 51C/SHIP2 protein. J. Biol. Chem. 273, 18605-18609 (1998).
61. Ishihara, H. et al. Molecular cloning of rat SH2-containing inositol phosphatase 2 (SHIP2) and its role in the regulation of insulin signaling. Biochem. Biophys. Res. Commun. 260, 265-272 (1999).
62. Blero, D. et al. The SH2 domain containing inositol 5-phosphatase SHIP2 controls phosphatidylinositol 3,4,5-trisphosphate levels in CHO-IR cells stimulated by insulin. Biochem. Biophys. Res. Commun. 282, 839-843 (2001).
63. Wada, T. et al. Overexpression of SH2-containing inositol phosphatase 2 results in negative regulation of insulin-induced metabolic actions in 3T3-L1 adipocytes via its 5′-phosphatase catalytic activity. Mol. Cell. Biol. 21, 1633-1646 (2001).
64. Sasaoka, T. et al. SH2-containing inositol phosphatase 2 predominantly regulates Akt2, and not Akt1, phosphorylation at the plasma membrane in response to insulin in 3T3-L1 adipocytes. J. Biol. Chem. 279, 14835-14843 (2004).
65. Wada, T. et al. Role of the Src homology 2 (SH2) domain and C-terminus tyrosine phosphorylation sites of SH2-containing inositol phosphatase (SHIP) in the regulation of insulin-induced mitogenesis. Endocrinology 140, 4585-4594 (1999).
66. Sharma, P. M., Son, H. S., Ugi, S., Ricketts, W. & Olefsky, J. M. Mechanism of SHIP-mediated inhibition of insulin- and platelet-derived growth factor-stimulated mitogen-activated protein kinase activity in 3T3-L1 adipocytes. Mol. Endocrinol. 19, 421-430 (2005).
67. Sasaoka, T. et al. SH2-containing inositol phosphatase 2 negatively regulates insulin-induced glycogen synthesis in L6 myotubes. Diabetologia 44, 1258-1267 (2001).
68. Murakami, S. et al. Impact of Src homology 2-containing inositol 5′-phosphatase 2 on the regulation of insulin signaling leading to protein synthesis in 3T3-L1 adipocytes cultured with excess amino acids. Endocrinology 145, 3215-3223 (2004).
69. Cho, H. et al. Insulin resistance and a diabetes mellituslike syndrome in mice lacking the protein kinase Akt2 (PKBβ). Science 292, 1728-1731 (2001).
70. Bae, S. S., Cho, H., Mu, J. & Birnbaum, M. J. Isoformspecific regulation of insulin-dependent glucose uptake by Akt/protein kinase B. J. Biol. Chem. 278, 49530-49536 (2003).
71. Garofalo, R. S. et al. Severe diabetes, age-dependent loss of adipose tissue, and mild growth deficiency in mice lacking Akt2/PKBβ. J. Clin. Invest. 112, 197-208 (2003).
72. Sasaoka, T. et al. Inhibition of endogenous SHIP2 ameliorates insulin resistance caused by chronic insulin treatment in 3T3-L1 adipocytes. Diabetologia 48, 336-344 (2005).
73. Clement, S. et al. The lipid phosphatase SHIP2 controls insulin sensitivity. Nature 409, 92-97 (2001).
74. Clement, S. et al. corrigenda: The lipid phosphatase SHIP2 controls insulin sensitivity. Nature 431, 878 (2004).
75. Manning, B. D. Balancing Akt with S6K: Implications for both metabolic diseases and tumorigenesis. J. Cell. Biol. 167, 399-403 (2004).
76. Chiang, S. H. et al. Insulin-stimulated GLUT4 translocation requires the CAP-dependent activation of TC10. Nature 410, 944-948 (2001).
77. Elchebly, M. et al. Increased insulin sensitivity and obesity resistance in mice lacking the protein tyrosine phosphatase-1B gene. Science 283, 1544-1548 (1999).
78. Klaman, L. D. et al. Increased energy expenditure, decreased adiposity, and tissue-specific insulin sensitivity in protein-tyrosine phosphatase 1B-deficient mice. Mol. Cell. Biol. 20, 5479-5489 (2000).
79. Plum, L., Schubert, M. & Bruning, J. C. The role of insulin receptor signaling in the brain. Trends Endocrinol. Metab. 16, 59-65 (2005).
80. Niswender, K. D. & Schwartz, M. W. Insulin and leptin revisited: adiposity signals with overlapping physiological and intracellular signaling capabilities. Front Neuroendocrinol. 24, 1-10 (2003).
81. Niswender, K. D., Baskin, D. G. & Schwartz, M. W. Insulin and its evolving partnership with leptin in the hypothalamic control of energy homeostasis. Trends Endocrinol. Metab. 15, 362-369 (2004).
82. Gerozissis, K. Brain insulin and feeding: A bi-directional communication. Eur J Pharmacol 490, 59-70 (2004).
83. Porte, D., Jr., Baskin, D. G. & Schwartz, M. W. Insulin signaling in the central nervous system: A critical role in metabolic homeostasis and disease from C. elegans to humans. Diabetes 54, 1264-1276 (2005).
84. Burks, D. J. et al. IRS-2 pathways integrate female reproduction and energy homeostasis. Nature 407, 377-382 (2000).
85. Masaki, T. et al. Obesity in insulin receptor substrate-2-deficient mice: Disrupted control of arcuate nucleus neuropeptides. Obes. Res. 12, 878-885 (2004).
86. Bruning, J. C. et al. Role of brain insulin receptor in control of body weight and reproduction. Science 289, 2122-2125 (2000).
87. Obici, S., Feng, Z., Karkanias, G., Baskin, D. G. & Rossetti, L. Decreasing hypothalamic insulin receptors causes hyperphagia and insulin resistance in rats. Nature Neurosci. 5, 566-572 (2002).
88. Xu, A. W. et al. PI3K integrates the action of insulin and leptin on hypothalamic neurons. J. Clin. Invest. 115, 951-958 (2005).
89. Carvalheira, J. B. et al. Cross-talk between the insulin and leptin signaling systems in rat hypothalamus. Obes. Res. 13, 48-57 (2005).
90. Rahmouni, K. et al. Hypothalamic PI3K and MAPK differentially mediate regional sympathetic activation to insulin. J. Clin. Invest. 114, 652-658 (2004).
91. Fisher, S. J., Bruning, J. C., Lannon, S. & Kahn, C. R. Insulin signaling in the central nervous system is critical for the normal sympathoadrenal response to hypoglycemia. Diabetes 54, 1447-1451 (2005).
92. Mirshamsi, S. et al. Leptin and insulin stimulation of signalling pathways in arcuate nucleus neurones: PI3K dependent actin reorganization and KATP channel activation. BMC Neurosci. 5, 54 (2004).
93. Pocai, A. et al. Hypothalamic K(ATP) channels control hepatic glucose production. Nature 434, 1026-1031 (2005).
94. Clegg, D. J. et al. Reduced anorexic effects of insulin in obesity-prone rats fed a moderate-fat diet. Am. J. Physiol. Regul. Integr. Comp. Physiol. 288, R981-R986 (2005).
95. De Souza, C. T. et al. Consumption of a fat-rich diet activates a pro-inflammatory response and induces insulin resistance in the hypothalamus. Endocrinology 146, 4192-4199 (2005).
96. Lin, S., Thomas, T. C., Storlien, L. H. & Huang, X. F. Development of high fat diet-induced obesity and leptin resistance in C57Bl/6J mice. Int. J. Obes. Relat. Metab. Disord. 24, 639-646 (2000).
97. Lin, L., Martin, R., Schaffhauser, A. O. & York, D. A. Acute changes in the response to peripheral leptin with alteration in the diet composition. Am. J. Physiol. Regul. Integr. Comp. Physiol. 280, R504- R509 (2001).
98. Wilsey, J., Zolotukhin, S., Prima, V. & Scarpace, P. J. Central leptin gene therapy fails to overcome leptin resistance associated with diet-induced obesity. Am. J. Physiol. Regul. Integr. Comp. Physiol. 285, R1011-R1020 (2003).
99. Lu, H. et al. Obesity due to high fat diet decreases the sympathetic nervous and cardiovascular responses to intracerebroventricular leptin in rats. Brain Res. Bull. 47, 331-335 (1998).
100. Zabolotny, J. M. et al. PTP1B regulates leptin signal transduction in vivo. Dev. Cell 2, 489-95 (2002).
101. Cheng, A. et al. Attenuation of leptin action and regulation of obesity by protein tyrosine phosphatase 1B. Dev. Cell 2, 497-503 (2002).
102. Schulingkamp, R. J., Pagano, T. C., Hung, D. & Raffa, R. B. Insulin receptors and insulin action in the brain: Review and clinical implications. Neurosci. Biobehav. Rev. 24, 855-872 (2000).
103. Tartaglia, L. A. et al. Identification and expression cloning of a leptin receptor, OB-R. Cell 83, 1263-71 (1995).
104. Kurrimbux, D., Gaffen, Z., Farrell, C. L., Martin, D. & Thomas, S. A. The involvement of the blood-brain and the blood-cerebrospinal fluid barriers in the distribution of leptin into and out of the rat brain. Neuroscience 123, 527-536 (2004).
105. Muraille, E. et al. The SH2 domain-containing 5-phosphatase SHIP2 is expressed in the germinal layers of embryo and adult mouse brain: increased expression in N-CAM-deficient mice. Neuroscience 105, 1019-1030 (2001).
106. Hori, H. et al. Association of SH2-containing inositol phosphatase 2 with the insulin resistance of diabetic db/db mice. Diabetes 51, 2387-2394 (2002).
107. Fukui, K. et al. Impact of the liver-specific expression of SHIP2 (SH2-containing inositol 5′-phosphatase 2) on insulin signaling and glucose metabolism in mice. Diabetes 54, 1958-1967 (2005).
108. Marion, E. et al. The gene INPPL1, encoding the lipid phosphatase SHIP2, is a candidate for type 2 diabetes in rat and man. Diabetes 51, 2012-2017 (2002).
109. Kaisaki, P. J. et al. Polymorphisms in type II SH2 domain-containing inositol 5-phosphatase (INPPL1, SHIP2) are associated with physiological abnormalities of the metabolic syndrome. Diabetes 53, 1900-1904 (2004).
110. Kagawa, S. et al. Impact of SRC homology 2-containing inositol 5′-phosphatase 2 gene polymorphisms detected in a Japanese population on insulin signaling. J. Clin. Endocrinol. Metab. 90, 2911-2919 (2005).
111. Prasad, N., Topping, R. S. & Decker, S. J. SH2-containing inositol 5′-phosphatase SHIP2 associates with the p130(Cas) adapter protein and regulates cellular adhesion and spreading. Mol. Cell. Biol. 21, 1416-1428 (2001).
112. Koch, A., Mancini, A., El Bounkari, O. & Tamura, T. The SH2-domian-containing inositol 5-phosphatase (SHIP)-2 binds to c-Met directly via tyrosine residue 1356 and involves hepatocyte growth factor (HGF)-induced lamellipodium formation, cell scattering and cell spreading. Oncogene 24, 3436-3447 (2005).
113. Giuriato, S. et al. SHIP2 overexpression strongly reduces the proliferation rate of K562 erythroleukemia cell line. Biochem. Biophys. Res. Commun. 296, 106-110 (2002).
114. Taylor, V. et al. 5′ phospholipid phosphatase SHIP-2 causes protein kinase B inactivation and cell cycle arrest in glioblastoma cells. Mol. Cell. Biol. 20, 6860-6871 (2000).
115. Blero, D. et al. Phosphatidylinositol 3,4,5-trisphosphate modulation in SHIP2-deficient mouse embryonic fibroblasts. FEBS J. 272, 2512-2522 (2005).
116. Choi, Y. et al. PTEN, but not SHIP and SHIP2, suppresses the PI3K/Akt pathway and induces growth inhibition and apoptosis of myeloma cells. Oncogene 21, 5289-5300 (2002).
117. Wisniewski, D. et al. A novel SH2-containing phosphatidylinositol 3,4,5-trisphosphate 5-phosphatase (SHIP2) is constitutively tyrosine phosphorylated and associated with src homologous and collagen gene (SHC) in chronic myelogenous leukemia progenitor cells. Blood 93, 2707-2720 (1999).
118. Helgason, C. D. et al. Targeted disruption of SHIP leads to hemopoietic perturbations, lung pathology, and a shortened life span. Genes Dev. 12, 1610-1620 1998).
119. Tsujishita, Y., Guo, S., Stolz, L. E., York, J. D. & Hurley, J. H. Specificity determinants in phosphoinositide dephosphorylation: Crystal structure of an archetypal inositol polyphosphate 5-phosphatase. Cell 105, 379-389 (2001).
120. Fisher, D. K. & Higgins, T. J. A sensitive, high-volume, colorimetric assay for protein phosphatases. Pharm. Res. 11, 759-763 (1994).
121. Maehama, T., Taylor, G. S., Slama, J. T. & Dixon, J. E. A sensitive assay for phosphoinositide phosphatases. Anal. Biochem. 279, 248-250 (2000).
122. Drees, B. E. et al. Competitive fluorescence polarization assays for the detection of phosphoinositide kinase and phosphatase activity. Comb. Chem. High Throughput Screen. 6, 321-330 (2003).
123. Gray, A., Olsson, H., Batty, I. H., Priganica, L. & Peter Downes, C. Nonradioactive methods for the assay of phosphoinositide 3-kinases and phosphoinositide phosphatases and selective detection of signaling lipids in cell and tissue extracts. Anal. Biochem. 313, 234-245 (2003).
124. Oatey, P. B. et al. Confocal imaging of the subcellular distribution of phosphatidylinositol 3,4,5-trisphosphate in insulin- and PDGF-stimulated 3T3-L1 adipocytes. Biochem. J. 344, 511-518 (1999).
125. Sato, M., Ueda, Y., Takagi, T. & Umezawa, Y. Production of PtdInsP3 at endomembranes is triggered by receptor endocytosis. Nature Cell. Biol. 5, 1016-1022 (2003).
126. Tengholm, A., Teruel, M. N. & Meyer, T. Single cell imaging of PI3K activity and glucose transporter insertion into the plasma membrane by dual color evanescent wave microscopy. Sci STKE 2003, PL4 (2003).
127. Niswender, K. D. et al. Immunocytochemical detection of phosphatidylinositol 3-kinase activation by insulin and leptin. J. Histochem. Cytochem. 51, 275-283 (2003).
128. Wiesmann, C. et al. Allosteric inhibition of protein tyrosine phosphatase 1B. Nature Struct. Mol. Biol. 11, 730-737 (2004).
129. Yang, L. et al. Synthesis of pelorol and analogues: Activators of the inositol 5-phosphatase SHIP. Org. Lett. 7, 1073-1076 (2005).